ADA 2021 Highlights

Política de privacidad.

Disponible en la aplicación Medfyle

Bienvenido a lo más destacados de ADA 2021

Las Sesiones Científicas Virtuales de la ADA de 2021 ofrecieron a los investigadores y a los profesionales de la salud la oportunidad única de compartir ideas y conocer los importantes avances y progresos en materia de diabetes. Con más de 180 sesiones y 1.000 presentaciones de investigaciones originales, las Sesiones Científicas, celebradas del 25 al 29 de junio, ofrecieron una programación educativa completa que cubrió lo último en el campo de la diabetes. Nos complace presentar estas selecciones de lo más destacado de ADA.


Bienvenido a Today@ADA – un resumen de nuestras selecciones del programa del día en las 81ª Sesiones Científicas de la Asociación Americana de Diabetes. Cada día, Dana Dabelea, presidenta del Comité de Planificación de las 81ª Sesiones Científicas de la ADA, le ofrecerá una entrevista con uno de los principales ponentes de las 81ª Sesiones Científicas de la ADA, así como una presentación de sus tres principales selecciones de todo lo que se presentó en directo, con opiniones y comentarios personales.
Puede volver a ver todo lo que se perdió y ponerse al día en las sesiones bajo demanda.

Entrevistas a directivos de ADA

What are your objectives for your term as President of Health Care & Education at the ADA?
What will be the long-term professional impact of COVID-19 on clinical care for people with diabetes?
How did the pandemic brought an epidemic to light?
What are some of the more common mental health issues faced by children with diabetes” or children with insulin-treated diabetes?
How has the overall ADA strategy changed as a result of the pandemic? What does the future hold?
The COVID-19 pandemic has disrupted life as we knew it, but it has also offered opportunities – what would you say has changed for the better in diabetes as a result of the pandemic?
ADA, together with the EASD, is working on a new consensus report on the management of type 1 diabetes in adults: What’s new?
You are only the fifth women to hold the position of ADA President, Science & Medicine - for many years, research and clinical trials involved only men, how important is it for young female diabetologists to be part of the future of research in diabetes?
As Chief Scientific & Medical Officer at the ADA, what are your goals for the association?
How important is the partnership with patient organizations, and how does it benefit physicians and people with diabetes?
Your research focuses on innovative models of diabetes care. In this regard, what is the ADA doing to improve the lives of people with diabetes?

Entrevistas al profesorado de ADA

What percentage of people with type 2 diabetes have cardiorenal complications?
What are the key metabolic risks?
What role do SGLT2 inhibitors and GLP-1 receptor agonists have to play?
How many people who need these agents receive them?
What needs to change to fully mitigate cardiorenal risks?
Is there a perception that diabetes care is not the responsibility of cardiologists?
What is the link between diabetes and cardiovascular outcomes?
What have we learnt from the cardiovascular outcomes trials with SGLT2 inhibitors and GLP-1 receptor agonists?
What role could these agents play in the inpatient cardiovascular care setting?
What did you hope to show with the TrialNet study?
Have there been any surprises in the results?
How can this information shape future treatment options for type 1 diabetes?
Ver más

Resúmenes de expertos

Ver más


Ver más


Ver más
Sobre ADA Feedback Prueba de nivel